USD/JPY Fades Pfizer Move, but May Be Ready for a Bounce

Technically, traders may see a good risk/reward opportunity near current levels.

FOREX 7

The positive Pfizer vaccine news from last Monday caused a spike in USD/JPY, as the pair moved from 103.30 up to 105.35, a gain of 205 pips!  However, as shown by the price move in USD/JPY yesterday, positive vaccine news may already be priced into the pair.  USD/JPY opened at 104.60 and closed at 104.07, a loss of 53 pips.  Technically though, traders may see a good risk/reward opportunity near current levels.

On a daily timeframe, USD/JPY has been moving lower since the March 24th highs at 111.715 in a descending wedge formation and is currently nearing the apex of the wedge. On November 4th, the pair pushed lower through horizontal support, and tested the bottom trendline of the wedge. 

Source: Tradingview, City Index

On a shorter, 60-minute timeframe,  traders can see the large move from the bottom trendline of the wedge to the topline of the wedge.  But notice the price action after the positive vaccine news from Moderna.  Price did spike higher but was quickly faded.  USD/JPY now sits at the 61.8% Fibonacci retracement level from the low to high on November 9th.  In addition, it is sitting just above horizontal support near 104.00 and the RSI has just moved from oversold territory back into neutral territory. 

Source: Tradingview, City Index

Bulls will look to buy between 104 and 104.20, targeting the top trendline of the wedge and place stops below the horizontal support just below.  If price breaks below 104, watch for bears to sell retests of the 104.00 area, targeting the recent lows at 103.20 and then the downward sloping trendline, with stops above 104.00.


From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.